Medical/Pharmaceuticals News & Press Release Distribution

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 22:31 2204

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 22:20 2263

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:34 1870

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:30 1957

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof.Weiming Li, ...

2024-12-10 21:27 1841

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:26 1461

Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care

– Collaboration combines Terumo's ePRISM™ precision medicine software platform withMedis' QFR® technology – SOMERSET, N.J., Dec. 10, 2024 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software...

2024-12-10 21:00 969

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 20:48 1741

PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series

MONTVALE, N.J., Dec. 10, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series—PENTAX Medical Video Colonoscope EC34-i20cL, PENTAX Medical Video Upper GI Scope EG27‑i20c and Right/Left W...

2024-12-10 20:00 840

PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (...

2024-12-10 10:18 1339

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today shared findings via a poster ...

2024-12-10 10:00 1312

$IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH$

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-12-10 08:30 1602

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients withHuntington's Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON, Dec. 10, 2024 /PRNewswire/ -- Skyhawk Therapeu...

2024-12-10 00:47 1466

2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)

NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezol...

2024-12-09 23:00 1678

TraceLink Successfully Completes Industry-Leading Audits: ISO/IEC 27001:2022, ISO/IEC 27017:2015, SOC 2/ISAE 3000 Type II, and CyberVadis

Independent Audits Confirm TraceLink's Compliance with Leading Global Security Standards, Ensuring Customer Data Protection BOSTON, Dec. 9, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has reinforced its leader...

2024-12-09 23:00 1401

Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW

Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer d...

2024-12-09 22:00 1639

Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW

WAT Medical Sponsors American Headache Society 2024 Scottsdale Headache Symposium

VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- WAT Medical Enterprise proudly sponsored the 2024 Scottsdale Headache Symposium, organized by the American Headache Society fromNovember 14-17 in Scottsdale, AZ. This annual event brought together a multidisciplinary audience of neurologists, general p...

2024-12-09 22:00 959

WAT Medical Sponsors American Headache Society 2024 Scottsdale Headache Symposium

Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea

* MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center * Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNe...

2024-12-09 22:00 2090

Seoul National University Bundang Hospital Establishes the first

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...

2024-12-09 21:00 1586

Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate

BEIJING, Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that the National Medical Products Administration of...

2024-12-09 20:30 1601